摘要
目的:观察黄芪注射液联合米力农治疗充血性心力衰竭的临床疗效及安全性。方法:将76例充血性心力衰竭患者随机分成两组,其中治疗组38人,对照组38人。所有患者均采取使用利尿剂、口服血管紧张素转换酶抑制药等常规治疗,治疗组患者在常规治疗基础上采用米力农联合黄芪注射液治疗,对照组患者在常规治疗基础上采用米力农治疗,从临床疗效、心衰疗效计分、心率、心脏指数、心输出量及左心室射血分数指标进行评价。结果:治疗组的临床疗效、心衰疗效计分、心率、左心室射血分数与对照组相比,有统计学差异(P<0.05)。结论:黄芪注射液联合米力农治疗充血性心力衰竭的临床疗效优于单纯应用米力农。
Objective： To observe the clinical effect and security of Milrinone combined with Huangqi Injection in the treatment of Congestive heart failure. Methods： 76 patients with Congestive heart failure were randomly divided into the treating group（38people） and control group （38people）, All patients received the routine treatment of diuretics and oral taking of angiotensin converting enzyme,while patients in the treating group received the treatment of Milrinone combined with Huangqi Injection and those in the control group received the treatment of Milrinone. Compared the indicators of clinical effect, score of the effect of heart failure, heart rate （HR）, cardiac index （CI）, cardiac output （CO） and left ventricular ejection fraction （LVEF）. Results： There is significantly statistical difference comparing the clinical effect, score of the effect of heart failure, heart rate, left ventricular ejection fraction the two group （P 〈0.05）. Conclusion： The clinical efficacy of the Milrinone combined with Huangqi Injection is superior to Milrinone for treating the Congestive heart failure.
出处
《现代生物医学进展》
CAS
2012年第27期5313-5315,5301,共4页
Progress in Modern Biomedicine
